Can Thumbs UP: The Prevention arm of the Canadian Consortium on Neurodegeneration in Aging (CCNA)

Сохранить в:
Библиографические подробности
Опубликовано в::Alzheimer's & Dementia vol. 21 (Dec 1, 2025)
Главный автор: Belleville, Sylvie
Другие авторы: Anderson, Nicole D., Brewster, Paul W.H., Lim, Andrew, Montero‐Odasso, Manuel, Nygaard, Haakon B., Feldman, Howard H., Chertkow, Howard
Опубликовано:
John Wiley & Sons, Inc.
Предметы:
Online-ссылка:Citation/Abstract
Full Text - PDF
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

MARC

LEADER 00000nab a2200000uu 4500
001 3286868863
003 UK-CbPIL
022 |a 1552-5260 
022 |a 1552-5279 
024 7 |a 10.1002/alz70858_100229  |2 doi 
035 |a 3286868863 
045 0 |b d20251201 
100 1 |a Belleville, Sylvie  |u Institut Universitaire de Gériatrie de Montréal, Montréal, QC, Canada, 
245 1 |a Can Thumbs UP: The Prevention arm of the Canadian Consortium on Neurodegeneration in Aging (CCNA) 
260 |b John Wiley & Sons, Inc.  |c Dec 1, 2025 
513 |a Journal Article 
520 3 |a Background In 2019 Canadian dementia researchers launched the “The Canadian Therapeutic Platform Trial for Multidomain Interventions to Prevent Dementia” (CAN‐THUMBS UP; CTU), a national program to advance dementia prevention in Canada and globally. The initiative responded to findings demonstrating that lifestyle interventions could improve cognitive decline and to the Lancet Commission's report that over 40% of dementia cases might be prevented through risk factor mitigation. Method A major focus of CTU was developing and validating the Brain Health PRO Program, a 45‐week, bilingual, web‐based educational intervention addressing modifiable risk factors. The program consists of 181 ten‐minute chapters delivered incrementally on a weekly basis. It was designed to foster engagement and convey the best available evidence for lifestyle changes. A total of 345 participants self‐registered, completed initial questionnaires and gained access to the intervention. Dementia literacy, the primary outcome, was measured with the Alzheimer's Disease Knowledge Scale. Secondary outcomes included self‐efficacy (General Self‐Efficacy Scale), attitude toward dementia, user experience (System Usability Scale and Technology Acceptance Model Questionnaire), lifestyle, standard cognitive testing, smartphone‐based cognitive assessment, 24‐hour continuous mobility and sleep measures using actigraphy and sleep EEG wearables (Feldman, Belleville et al. 2023). Result The validation study successfully achieved its primary outcome of improving dementia literacy. Positive effects were also observed for secondary outcomes, including self‐efficacy and user satisfaction, with preliminary evidence suggesting a reduction in modifiable risk factors. Three additional studies leveraged the CTU infrastructure: SYNERGIC@Home, assessing the feasibility of a home‐based intervention to improve gait and cognition; SYNERGIC‐2, a randomized controlled trial testing a 12‐month home‐based personalized multidomain intervention in individuals at risk for dementia, using Brain Health PRO as a control condition; and an implementation sub‐study conducted in collaboration with the Federation of Quebec Alzheimer Societies. Conclusion CTU reflects a vibrant, collaborative effort of over 100 investigators, staff, citizen advisors, and partners. Leveraging CCNA's team structure, CTU incorporated contributions in study design, recruitment, technology, program evaluation and participatory research. Larger studies are underway within CCNA to confirm the efficacy of Brain Health PRO in mitigating dementia risk and to examine its implementation in diverse settings. 
653 |a National programmes 
653 |a Literacy 
653 |a Intervention 
653 |a Measures 
653 |a Collaboration 
653 |a Questionnaires 
653 |a Brain 
653 |a Dementia 
653 |a Technology 
653 |a Participatory research 
653 |a Cognition 
653 |a Efficacy 
653 |a Health 
653 |a Lifestyles 
653 |a Advisors 
653 |a Infrastructure 
653 |a Bilingual education 
653 |a Cognitive impairment 
653 |a Feasibility 
653 |a Recruitment 
653 |a Technology Acceptance Model 
653 |a Prevention 
653 |a Attitude measures 
653 |a Implementation 
653 |a Alzheimer's disease 
653 |a Gait 
653 |a Evaluation research 
653 |a Prevention programs 
653 |a Risk factors 
653 |a Mobility 
653 |a Clinical trials 
653 |a Mitigation 
653 |a Attitudes 
653 |a Aging 
653 |a Program evaluation 
653 |a Educational programs 
653 |a Validation studies 
653 |a Electroencephalography 
653 |a Sleep 
653 |a Satisfaction 
653 |a Actigraphy 
700 1 |a Anderson, Nicole D.  |u Rotman Research Institute, Toronto, ON, Canada, 
700 1 |a Brewster, Paul W.H.  |u University of Victoria, Victoria, BC, Canada, 
700 1 |a Lim, Andrew  |u Sunnybrook Research Institute, Toronto, ON, Canada, 
700 1 |a Montero‐Odasso, Manuel  |u Schulich School of Medicine & Dentistry, Division of Geriatric Medicine, Western University, London, ON, Canada, 
700 1 |a Nygaard, Haakon B.  |u University of British Columbia, Vancouver, BC, Canada, 
700 1 |a Feldman, Howard H.  |u University of California San Diego, La Jolla, CA, USA, 
700 1 |a Chertkow, Howard  |u Rotman Research Institute, Baycrest Health Sciences, Toronto, ON, Canada, 
773 0 |t Alzheimer's & Dementia  |g vol. 21 (Dec 1, 2025) 
786 0 |d ProQuest  |t Consumer Health Database 
856 4 1 |3 Citation/Abstract  |u https://www.proquest.com/docview/3286868863/abstract/embedded/H09TXR3UUZB2ISDL?source=fedsrch 
856 4 0 |3 Full Text - PDF  |u https://www.proquest.com/docview/3286868863/fulltextPDF/embedded/H09TXR3UUZB2ISDL?source=fedsrch